Omega Diagnostics (CNSL) Price & Analysis

Compare

4 Followers

CNSL Stock Chart & Stats

2.30p

-0.05p(-1.67%)

At close: Jan 09 4:00 PM EST

2.30p

-0.05p(-1.67%)

Day’s Range― - ―

52-Week Range1.80p - 4.33p

Previous CloseN/A

Volume6.91K

Average Volume (3M)353.57K

Market Cap

£4.76M

Enterprise Value1.40M

Total Cash (Recent Filing)£3.59M

Total Debt (Recent Filing)£237.00K

Price to Earnings (P/E)3.5

Beta1.28

Next Earnings

Jul 29, 2026

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding237,950,650

10 Day Avg. Volume111,535

30 Day Avg. Volume353,573

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.64

Price to Sales (P/S)0.87

P/FCF Ratio-51.18

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetExtremely low leverage and a double-digit ROE provide durable financial stability, giving the company flexibility to absorb shocks, fund targeted investments, and pursue strategic opportunities without immediate refinancing pressures, supporting medium-term resilience.

High Gross And Net MarginsSustained high gross and positive net margins indicate a profitable product mix and pricing power in in vitro diagnostics. These structural margins can support R&D, product quality, and selective commercial investment, underpinning long-term competitive positioning.

Management Alignment Via Share PurchasesSenior management buying shares signals alignment with shareholders and confidence in execution. This alignment tends to improve governance, incentivize long-term value creation, and reduce agency risk, supporting steadier strategic decision-making over months ahead.

Bears Say

Declining Revenue TrendConsistent revenue contraction erodes scale benefits and market share, increasing per-unit costs and stressing commercial channels. Over 2–6 months this trend can force tougher pricing, reduce investment capacity, and weaken negotiating power with customers and suppliers.

Severe Cash Flow DeteriorationMaterial negative free cash flow growth and poor cash conversion signal liquidity strain and weakened internal funding. Even with low debt, persistent cash shortfalls limit reinvestment, raise refinancing risk for capex or working capital, and constrain strategic flexibility long-term.

Operational Inefficiencies (negative EBIT)Negative EBIT alongside strong gross margins indicates rising operating costs or poor cost control. Structural operating inefficiency reduces ability to convert sales into sustainable profits, pressuring margins and requiring corrective actions to restore competitive economics.

Omega Diagnostics News

Cambridge Nutritional Sciences Leadership Increases Shareholdings

Omega Diagnostics ( ($GB:CNSL) ) has provided an update. Cambridge Nutritional Sciences plc announced that Carolyn Rand, Non-Executive...

3M ago

Cambridge Nutritional Sciences Reports Revenue Decline but Improves Gross Margin

Omega Diagnostics ( ($GB:CNSL) ) has shared an update. Cambridge Nutritional Sciences reported a decrease in revenue for...

4M ago

Cambridge Nutritional Sciences to Announce Half Year Results and Host Investor Presentation

Omega Diagnostics ( ($GB:CNSL) ) has issued an update. Cambridge Nutritional Sciences plc has announced it will release...

4M ago

Cambridge Nutritional Sciences Announces AGM and Annual Report Release

Omega Diagnostics ( ($GB:CNSL) ) has issued an update. Cambridge Nutritional Sciences plc has announced the finalization of...

6M ago

Cambridge Nutritional Sciences Grants Share Options to CFO

Omega Diagnostics ( ($GB:CNSL) ) has provided an update. Cambridge Nutritional Sciences Plc has announced the granting of...

6M ago

Cambridge Nutritional Sciences PLC Reports Strong Financial Performance Amidst Strategic Restructuring

Omega Diagnostics ( ($GB:CNSL) ) has shared an update. Cambridge Nutritional Sciences PLC reported its final results for...

6M ago

Cambridge Nutritional Sciences to Announce Final Results and Host Investor Presentation

The latest update is out from Omega Diagnostics ( ($GB:CNSL) ). Cambridge Nutritional Sciences plc announced it will...

7M ago

Cambridge Nutritional Sciences Appoints New CFO to Bolster Growth

Omega Diagnostics ( ($GB:CNSL) ) has issued an update. Cambridge Nutritional Sciences Plc has appointed Ajay Patel as...

8M ago

Cambridge Nutritional Sciences Appoints New CFO to Drive Growth

Omega Diagnostics ( ($GB:CNSL) ) just unveiled an announcement. Cambridge Nutritional Sciences Plc has appointed Ajay Patel as...

8M ago

Cambridge Nutritional Sciences PLC Adjusts Voting Rights Structure

Omega Diagnostics ( ($GB:CNSL) ) just unveiled an update. Cambridge Nutritional Sciences PLC has announced a change in...

8M ago

CNSL FAQ

What was Omega Diagnostics Group PLC’s price range in the past 12 months?

Omega Diagnostics Group PLC lowest share price was 1.80p and its highest was 4.33p in the past 12 months.

What is Omega Diagnostics Group PLC’s market cap?

Omega Diagnostics Group PLC’s market cap is £4.76M.

When is Omega Diagnostics Group PLC’s upcoming earnings report date?

Omega Diagnostics Group PLC’s upcoming earnings report date is Jul 29, 2026 which is in 156 days.

How were Omega Diagnostics Group PLC’s earnings last quarter?

Omega Diagnostics Group PLC released its earnings results on Nov 10, 2025. The company reported 0p earnings per share for the quarter, the consensus estimate of N/A by 0p.

Is Omega Diagnostics Group PLC overvalued?

According to Wall Street analysts Omega Diagnostics Group PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Omega Diagnostics Group PLC pay dividends?

Omega Diagnostics Group PLC does not currently pay dividends.

What is Omega Diagnostics Group PLC’s EPS estimate?

Omega Diagnostics Group PLC’s EPS estimate is >-0.01.

How many shares outstanding does Omega Diagnostics Group PLC have?

Omega Diagnostics Group PLC has 237,950,650 shares outstanding.

What happened to Omega Diagnostics Group PLC’s price movement after its last earnings report?

Omega Diagnostics Group PLC reported an EPS of 0p in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -15.094%.

Which hedge fund is a major shareholder of Omega Diagnostics Group PLC?

Currently, no hedge funds are holding shares in GB:CNSL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Omega Diagnostics Group PLC

Cambridge Nutritional Sciences plc, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market. The company is involved in the research, development, and production of kits for detection of immune reactions to food under the Foodprint name. It provides clinical analysis to the general public, clinics, and health professionals, as well as supplies Food Detective, a consumer food test. The company serves government, private hospitals, reference laboratories, nutritionists, naturopaths, and other healthcare professionals. Cambridge Nutritional Sciences plc operates in the United Kingdom, rest of Europe, North America, South/Central America, India, other Asian countries and the Far East, Africa, and the Middle East. The company was formerly known as Omega Diagnostics Group PLC and changed its name to Cambridge Nutritional Sciences plc in September 2023. Cambridge Nutritional Sciences plc was founded in 1987 and is based in London, the United Kingdom.